Therefore, these potential variations in GC production by the mother together with the potential modulation of MC2R expression levels by its genetic variant could affect the development and the response of the HPA axis in the fetus and modulated ALL risk. The gene discussed is MC2R; the disease is acute lymphoblastic leukemia.